You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Express Scripts
Mallinckrodt
Merck

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Litigation Details for RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 THE PATENTS-IN-SUIT 15. United States Patent No. 6,372,252 (the “’252 patent,” copy… which are protected by Plaintiff’s U.S Patent Nos. 6,372,252, 6,955,821, and 7,838,032. … INFRINGEMENT OF U.S. PATENT NO. 6,372,252 28. Plaintiff repeats… (10) Patent N0.: US 6,372,252 B1 Blume et al. …PageID: 17 U.S. Patent Apr. 16, 2002 Sheet 1 0f 11 US 6,372,252 B1 External link to document
0000-00-00 129 STIPULATION AND ORDER REGARDING U.S. PATENT NOS. 6,955,821 AND 7,838,032. Signed by Judge Renee Marie…2015 22 August 2017 1:15-cv-02155 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 130 STIPULATION AND ORDER REGARDING U.S. PATENT NO. 7,838,032. Signed by Judge Renee Marie Bumb on 4/4…2015 22 August 2017 1:15-cv-02155 830 Patent None District Court, D. New Jersey External link to document
0000-00-00 214 infringe U.S. Patent Nos. 6,372,252 (the “’252 Patent”), 6,955,821 (the “’821 Patent”), and 7,838,032…infringe the Patents-in-Suit. A. The ’821 Patent The ’821 Patent is entitled “Sustained…embodiment in the Patents-in-Suit. Tr. 235:13-15; see also ’821 Patent col. 12:46-56; ’032 Patent col. 17:45… ’252 Patent as to both Defendants [Docket Nos. 64, 65] and its claims under the ’821 Patent against…The ’821 Patent was filed on April 15, 2002, as Application No. 10/121,706. The ’821 Patent expires External link to document
0000-00-00 47 products) infringe its patents, specifically, Patent No. 6,372,252 (“‘252 Patent”), Patent No. 6,955,821 (“…(“‘821 Patent”), and Patent No. 7,838,032 (“‘032 Patent”) (collectively “the Patents”). The …The ‘032 Patent and ‘821 Patent are continuations-in-part of the ‘252 Patent. In relevant part, … As for the remaining two patents, the ‘821 Patent and ‘032 Patent, the material issue is whether…infringement as to the ‘252 Patent. As to the ‘821 and ‘032 Patents, Defendants contend that External link to document
0000-00-00 64 DEFENSES AND COUNTERCLAIMS AS CONCERNS U.S. PATENT NOS. 6,372,252 AND 6,955,821. Signed by Judge Renee Marie…2015 22 August 2017 1:15-cv-02155 830 Patent None District Court, D. New Jersey External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Medtronic
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.